Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...

Abatacept is linked to lower mortality and fewer hospitalizations than rituximab in patients with rheumatoid ...

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

Oxygen therapy is a treatment going back to the days of Ben Franklin. In 1783, a French physician was the first to use it, ...

Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according ...

A Right To Information (RTI) response from Mumbai’s three biggest civic-run hospitals shows that only 0.3% of respiratory ...

Inhalational exposures to smoking, asbestos, dust, metals, and organics significantly increase the odds of developing interstitial lung disease.

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

The impact that Bernie Williams’ father had on him was immeasurable. Without the sage advice and caring personality of ...

Investing in clinical-stage biotechnology always carries significant risks, and aTyr is no exception. The company reported a ...

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.